Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CAM-H2
i
Other names:
CAM-H2, 131-Iodine conjugated anti-HER2 sdAb 2Rs15d, Iodine-131-SGMIB anti-HER2 VHH1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Precirix
Drug class:
HER2 inhibitor, Ionizing radiation emitter
Related drugs:
‹
trastuzumab (407)
afatinib (227)
lapatinib (107)
neratinib (102)
pyrotinib (79)
tucatinib (39)
trastuzumab-pkrb (24)
margetuximab-cmkb (18)
poziotinib (17)
MCLA-128 (16)
KN026 (14)
mobocertinib (12)
trastuzumab-dttb (11)
ZW25 (10)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
trastuzumab-strf (8)
LZM-005 (8)
PRS-343 (8)
D3L-001 (7)
inetetamab (6)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
MT-5111 (4)
TAS2940 (4)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
MET306 (4)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
DZD9008 (3)
trastuzumab-IFN-β mutein (3)
AST-301 (2)
Bay846 (2)
CT-0508 (2)
DF1001 (2)
ER121 (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
SAR446309 (2)
BDC-1001 (2)
AB-201 (1)
ABL105 (1)
ACE1702 (1)
Hercease (trastuzumab biosimilar) (1)
BAY 2927088 (1)
BAY2701439 (1)
DZD1516 (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
EG12014 (trastuzumab biosimilar) (1)
IAH0968 (1)
IMM2902 (1)
MP0274 (1)
SAR443216 (1)
(1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
ZN-A-1041 (1)
S-222611 (1)
KD019 (1)
ABT-101 (0)
ADG138 (0)
ALT02 (trastuzumab biosimilar) (0)
trastuzumab biosimilar (AP062) (0)
B-Vaxx (0)
BAT1006 (0)
BAY2701438 (0)
BMS690514 (0)
CAT-179 (0)
CUDC-101 (0)
DA 3111 (trastuzumab biosimilar) (0)
(0)
ELVN-002 (0)
ES2B-C001 (0)
ETBX-021 (0)
(0)
GB235 (0)
HER-2/neu peptide vaccine (0)
HER2 t-haNK (0)
HF158K1 (0)
HLX11 (pertuzumab biosimilar) (0)
Hervycta (trastuzumab biosimilar) (0)
ISB 1302 (0)
JIN-A04 (0)
JNJ-26483327 (0)
OST-HER2 (0)
MBS301 (0)
MM 111 (0)
MP412 (0)
MVA-BN-HER2 (0)
NVL-330 (0)
NeuCeptin (trastuzumab biosimilar) (0)
nelipepimut-S (0)
lapuleucel-T (0)
OS47701 (0)
QP34563457 (0)
ertumaxomab (0)
trastuzumab biosimilar (SIBP-01) (0)
SPH5030 (0)
SSGJ-705 (0)
(0)
Sym013 (0)
TAC100-HER2 (0)
TAK-285 (0)
TAS0728 (0)
TPIV100 (0)
TQB2930 (0)
glycooptimized trastuzumab-GEX (0)
TrastuRel (trastuzumab biosimilar) (0)
Undisclosed HER2Bi-armed ATC (0)
VM 206 (0)
AST1306 (0)
cipatinib (0)
dHER2+AS15 (0)
IBI315 (0)
KBP-5209 (0)
RG6194 (0)
AZD8931 (0)
trastuzumab biosimilar (0)
trastuzumab biosimilar (0)
177Lu-satetraxetan-lilotomab (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
lutetium Lu 177 dotatate (2)
PNT2002 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
AAA603 (0)
iodine I 131 tositumomab (0)
samarium-153 DOTMP (0)
Debio 0228 (0)
EBTATE (0)
FF21101 (0)
ITM-31 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
Re (0)
trastuzumab (407)
afatinib (227)
lapatinib (107)
neratinib (102)
pyrotinib (79)
tucatinib (39)
trastuzumab-pkrb (24)
margetuximab-cmkb (18)
poziotinib (17)
MCLA-128 (16)
KN026 (14)
mobocertinib (12)
trastuzumab-dttb (11)
ZW25 (10)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
trastuzumab-strf (8)
LZM-005 (8)
PRS-343 (8)
D3L-001 (7)
inetetamab (6)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
MT-5111 (4)
TAS2940 (4)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
MET306 (4)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
DZD9008 (3)
trastuzumab-IFN-β mutein (3)
AST-301 (2)
Bay846 (2)
CT-0508 (2)
DF1001 (2)
ER121 (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
SAR446309 (2)
BDC-1001 (2)
AB-201 (1)
ABL105 (1)
ACE1702 (1)
Hercease (trastuzumab biosimilar) (1)
BAY 2927088 (1)
BAY2701439 (1)
DZD1516 (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
EG12014 (trastuzumab biosimilar) (1)
IAH0968 (1)
IMM2902 (1)
MP0274 (1)
SAR443216 (1)
(1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
ZN-A-1041 (1)
S-222611 (1)
KD019 (1)
ABT-101 (0)
ADG138 (0)
ALT02 (trastuzumab biosimilar) (0)
trastuzumab biosimilar (AP062) (0)
B-Vaxx (0)
BAT1006 (0)
BAY2701438 (0)
BMS690514 (0)
CAT-179 (0)
CUDC-101 (0)
DA 3111 (trastuzumab biosimilar) (0)
(0)
ELVN-002 (0)
ES2B-C001 (0)
ETBX-021 (0)
(0)
GB235 (0)
HER-2/neu peptide vaccine (0)
HER2 t-haNK (0)
HF158K1 (0)
HLX11 (pertuzumab biosimilar) (0)
Hervycta (trastuzumab biosimilar) (0)
ISB 1302 (0)
JIN-A04 (0)
JNJ-26483327 (0)
OST-HER2 (0)
MBS301 (0)
MM 111 (0)
MP412 (0)
MVA-BN-HER2 (0)
NVL-330 (0)
NeuCeptin (trastuzumab biosimilar) (0)
nelipepimut-S (0)
lapuleucel-T (0)
OS47701 (0)
QP34563457 (0)
ertumaxomab (0)
trastuzumab biosimilar (SIBP-01) (0)
SPH5030 (0)
SSGJ-705 (0)
(0)
Sym013 (0)
TAC100-HER2 (0)
TAK-285 (0)
TAS0728 (0)
TPIV100 (0)
TQB2930 (0)
glycooptimized trastuzumab-GEX (0)
TrastuRel (trastuzumab biosimilar) (0)
Undisclosed HER2Bi-armed ATC (0)
VM 206 (0)
AST1306 (0)
cipatinib (0)
dHER2+AS15 (0)
IBI315 (0)
KBP-5209 (0)
RG6194 (0)
AZD8931 (0)
trastuzumab biosimilar (0)
trastuzumab biosimilar (0)
177Lu-satetraxetan-lilotomab (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
lutetium Lu 177 dotatate (2)
PNT2002 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
AAA603 (0)
iodine I 131 tositumomab (0)
samarium-153 DOTMP (0)
Debio 0228 (0)
EBTATE (0)
FF21101 (0)
ITM-31 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
Re (0)
›
Associations
News
Trials
Filter by
Latest
4ms
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer (clinicaltrials.gov)
P1/2, N=13, Active, not recruiting, Precirix | Recruiting --> Active, not recruiting | N=70 --> 13 | Trial completion date: Jan 2025 --> Jan 2024 | Trial primary completion date: Jan 2025 --> Dec 2023
4 months ago
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
HER-2 positive
|
CAM-H2
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login